3
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      Malignant Sinonasal Tumors: Update on Histological and Clinical Management

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          Tumors of nasal cavity and paranasal sinuses (TuNSs) are rare and heterogeneous malignancies, presenting different histological features and clinical behavior. We reviewed the literature about etiology, biology, and clinical features of TuNSs to define pathologic features and possible treatment strategies. From a diagnostic point of view, it is mandatory to have high expertise and perform an immunohistochemical assessment to distinguish between different histotypes. Due to the extreme rarity of these neoplasms, there are no standard and evidence-based therapeutic strategies, lacking prospective and large clinical trials. In fact, most studies are retrospective analyses. Surgery represents the mainstay of treatment of TuNSs for small and localized tumors allowing complete tumor removal. Locally advanced lesions require more demolitive surgery that should be always followed by adjuvant radio- or chemo-radiotherapy. Recurrent/metastatic disease requires palliative chemo- and/or radiotherapy. Many studies emphasize the role of specific genes mutations in the development of TuNSs like mutations in the exons 4–9 of the TP53 gene, in the exon 9 of the PIK3CA gene and in the promoter of the TERT gene. In the near future, this genetic assessment will have new therapeutic implications. Future improvements in the understanding of the etiology, biology, and clinical features of TuNSs are warranted to improve their management.

          Related collections

          Most cited references100

          • Record: found
          • Abstract: found
          • Article: not found

          Induction chemotherapy plus radiation compared with surgery plus radiation in patients with advanced laryngeal cancer. The Department of Veterans Affairs Laryngeal Cancer Study Group.

          We performed a prospective, randomized study in patients with previously untreated advanced (Stage III or IV) laryngeal squamous carcinoma to compare the results of induction chemotherapy followed by definitive radiation therapy with those of conventional laryngectomy and postoperative radiation. Three hundred thirty-two patients were randomly assigned to receive either three cycles of chemotherapy (cisplatin and fluorouracil) and radiation therapy or surgery and radiation therapy. The clinical tumor response was assessed after two cycles of chemotherapy, and patients with a response received a third cycle followed by definitive radiation therapy (6600 to 7600 cGy). Patients in whom ther was no tumor response or who had locally recurrent cancers after chemotherapy and radiation therapy underwent salvage laryngectomy. After two cycles of chemotherapy, the clinical tumor response was complete in 31 percent of the patients and partial in 54 percent. After a median follow-up of 33 months, the estimated 2-year survival was 68 percent (95 percent confidence interval, 60 to 76 percent) for both treatment groups (P = 0.9846). Patterns of recurrence differed significantly between the two groups, with more local recurrences (P = 0.0005) and fewer distant metastases (P = 0.016) in the chemotherapy group than in the surgery group. A total of 59 patients in the chemotherapy group (36 percent) required total laryngectomy. The larynx was preserved in 64 percent of the patients overall and 64 percent of the patients who were alive and free of disease. These preliminary results suggest a new role for chemotherapy in patients with advanced laryngeal cancer and indicate that a treatment strategy involving induction chemotherapy and definitive radiation therapy can be effective in preserving the larynx in a high percentage of patients, without compromising overall survival.
            Bookmark
            • Record: found
            • Abstract: not found
            • Article: not found

            Tobacco smoke and involuntary smoking.

            (2004)
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Inflammation meets cancer, with NF-κB as the matchmaker.

              Inflammation is a fundamental protective response that sometimes goes awry and becomes a major cofactor in the pathogenesis of many chronic human diseases, including cancer. Here we review the evolutionary relationship and opposing functions of the transcription factor NF-κB in inflammation and cancer. Although it seems to fulfill a distinctly tumor-promoting role in many types of cancer, NF-κB has a confounding role in certain tumors. Understanding the activity and function of NF-κB in the context of tumorigenesis is critical for its successful taming, an important challenge for modern cancer biology.
                Bookmark

                Author and article information

                Journal
                Curr Oncol
                Curr Oncol
                curroncol
                Current Oncology
                MDPI
                1198-0052
                1718-7729
                01 July 2021
                August 2021
                : 28
                : 4
                : 2420-2438
                Affiliations
                [1 ]Nuclear Medicine Unit, Istituto Nazionale Tumori, IRCCS—Fondazione “G. Pascale”, 80131 Naples, Italy
                [2 ]Department of Pathology, Istituto Nazionale Tumori, IRCCS—Fondazione “G. Pascale”, 80131 Naples, Italy; f.tatangelo@ 123456istitutotumori.na.it (F.T.); n.losito@ 123456istitutotumori.na.it (N.S.L.)
                [3 ]Head and Neck Oncology Unit, Istituto Nazionale Tumori, IRCCS—Fondazione “G. Pascale”, 80131 Naples, Italy; f.perri@ 123456istitutotumori.na.it
                [4 ]Sarcomas and Rare Tumors Unit, Istituto Nazionale Tumori, IRCCS—Fondazione “G. Pascale”, 80131 Naples, Italy; giuseppedilorenzo10@ 123456gmail.com (G.D.L.); ottavia.clemente@ 123456istitutotumori.na.it (O.C.); s.tafuto@ 123456istitutotumori.na.it (S.T.)
                [5 ]Neurosurgery Unit, Federico II University, 80131 Naples, Italy; rob.tafuto@ 123456gmail.com
                [6 ]Division of Innovative Therapies for Abdominal Metastases, Istituto Nazionale Tumori, IRCCS—Fondazione “G. Pascale”, 80131 Naples, Italy; a.ottaiano@ 123456istitutotumori.na.it (A.O.); mariachiara.santorsola@ 123456istitutotumori.na.it (M.S.)
                [7 ]Radiology Unit, Istituto Nazionale Tumori, IRCCS—Fondazione “G. Pascale”, 80131 Naples, Italy; m.barretta@ 123456istitutotumori.na.it
                Author notes
                Author information
                https://orcid.org/0000-0002-9943-6079
                https://orcid.org/0000-0001-8158-7509
                https://orcid.org/0000-0001-6634-7865
                https://orcid.org/0000-0002-2901-3855
                https://orcid.org/0000-0002-3019-354X
                Article
                curroncol-28-00222
                10.3390/curroncol28040222
                8293118
                34287240
                58042423-185b-4679-b9db-bfb81619f403
                © 2021 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https://creativecommons.org/licenses/by/4.0/).

                History
                : 26 April 2021
                : 29 June 2021
                Categories
                Review

                Oncology & Radiotherapy
                sinonasal neuroendocrine neoplasms,tumors of sinonasal tract,ethmoid sinus salivary gland type,neuroendocrine carcinomas of the head and neck

                Comments

                Comment on this article